Attached files
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 27, 2013
SCIENTIFIC INDUSTRIES, INC.
______________________________________________________
(Exact name of registrant as specified in its charter)
Delaware 000-6658 04-2217279
_______________ _____________ __________________
(State or other (Commission (IRS Employer No.)
jurisdiction of File Number)
incorporation)
70 Orville Drive
Bohemia, New York 11716
__________________________________________________
(Address of principal executive offices)
(631) 567-4700
__________________________________________________
Registrant's telephone number, including area code
Not Applicable
__________________________________________________
(Former name or former address,
if changed since last report)
ITEM 1.02. Termination of a Material Definitive Agreement
See Item 8.01 for termination of the Research and Development
Agreement between BioDox R&D Corporation and the Company's
subsidiary, Scientific Bioprocessing, Inc.
ITEM 8.01. Termination of a Material Definitive Agreement
In June 2013, Scientific Bioprocessing, Inc, a wholly-owned
subsidiary of the Company, terminated its Research and
Development Agreement with BioDox R&D Corporation
(the "Developer") formerly Fluorometrix Inc., pursuant to
Section 7.2(b)(iii) of the Agreement due to the death of
Dr. Joseph E. Qualitz, the Developer's Chief Operating Officer.
The R&D Agreement provides that the Agreement terminate
immediately upon the cessation of Qualitz "to carry out and be
responsible for the day-to-day business operation of Developer
unless the Company consents in writing to a replacement who has
similar skills, education, experience and capabilities." The
Company believes that the termination will not be materially
adverse to the Company's operation or financial condition as it
believes the research and development can be performed by its
staff, or if needed, through qualified subcontractors at no
additional material increase in cost from that to be incurred
if the agreement was not terminated.
ITEM 9.01 Financial Statements and Exhibits
(a) and (b) not applicable
(c) Exhibits
Exhibit No. Exhibit
___________ _____________________________
99.1 Research and Development Agreement between
Scientific Bioprocessing, Inc, and BioDox
R&D Corporation, dated November 14, 2011
(incorporated hereto by reference to Exhibit 10(B)
to Current Report on Form 8-K, dated November 14, 2011)
99.2 Notice of Termination of Reseearch and Development
Agreement
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
SCIENTIFIC INDUSTRIES, INC.
(Registrant)
Date: June 27, 2013
By: /s/ Helena R. Santos
________________________
Helena R. Santos,
President and Chief Executive
Officer
